OXYMETAZOLINE HYDROCHLORIDE
Clinical safety rating: safe
MAOIs can cause hypertensive crisis Can cause rebound congestion (rhinitis medicamentosa) with prolonged use.
Alpha-1 adrenergic receptor agonist; causes vasoconstriction of nasal mucosa blood vessels.
| Metabolism | Not extensively metabolized; primarily renal excretion of unchanged drug. |
| Excretion | Primarily renal excretion of unchanged drug and metabolites; approximately 30-40% excreted unchanged in urine within 24 hours; minor biliary/fecal elimination (<5%). |
| Half-life | Terminal elimination half-life is approximately 5-8 hours; clinical effects may persist longer due to prolonged receptor occupancy. |
| Protein binding | None significant; negligible protein binding. |
| Volume of Distribution | Approximately 0.2-0.4 L/kg; indicates distribution mainly in extracellular fluid. |
| Bioavailability | Intranasal: minimal systemic absorption (<1% with therapeutic doses); ophthalmic: negligible systemic absorption. |
| Onset of Action | Intranasal: 1-5 minutes; ophthalmic: 5-10 minutes. |
| Duration of Action | Intranasal: 4-6 hours (up to 12 hours with longer-acting formulations); ophthalmic: 4-6 hours; prolonged use may cause rebound congestion. |
2-3 sprays per nostril of a 0.05% solution every 10-12 hours, not to exceed 2 doses in 24 hours. Applied intranasally.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Children 6-12 years: 1 spray per nostril of 0.05% solution every 10-12 hours, not to exceed 2 doses in 24 hours. Children 2-5 years: 1 spray per nostril of 0.025% solution every 10-12 hours, not to exceed 2 doses in 24 hours. Avoid use in children under 2 years. |
| Geriatric use | Use with caution due to potential increased sensitivity; dosing same as adults, but limit use to 3-5 days to avoid rhinitis medicamentosa. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
MAOIs can cause hypertensive crisis Can cause rebound congestion (rhinitis medicamentosa) with prolonged use.
| FDA category | Animal |
| Breastfeeding | Oxymetazoline is minimally excreted into breast milk after topical nasal administration. The M/P ratio is unknown, but due to low systemic absorption, it is considered compatible with breastfeeding. However, to avoid any risk of infant exposure, use the lowest effective dose for the shortest duration. Avoid use just before nursing if possible. No adverse effects in breastfed infants have been reported. |
| Teratogenic Risk |
■ FDA Black Box Warning
None
| Common Effects | Rebound congestion |
| Serious Effects |
["Hypersensitivity to oxymetazoline","Narrow-angle glaucoma","Transsphenoidal hypophysectomy","Use with MAO inhibitors or within 14 days"]
| Precautions | ["Rebound congestion (rhinitis medicamentosa) with prolonged use (>3 days)","Avoid use in patients with narrow-angle glaucoma","Caution in hypertension, cardiovascular disease, hyperthyroidism, diabetes, prostatic hyperplasia"] |
Loading safety data…
| Oxymetazoline hydrochloride is an imidazoline sympathomimetic with vasoconstrictive activity. Data on teratogenic risk in humans are limited. Animal studies have not shown evidence of fetal harm at doses higher than the maximum recommended human dose. In pregnancy, systemic absorption after topical nasal application is minimal, but theoretical risk of uteroplacental vasoconstriction exists. The FDA pregnancy category has not been assigned due to lack of adequate studies; however, use in the first trimester should be avoided if possible. In the second and third trimesters, short-term use for nasal congestion may be considered with caution; prolonged use may lead to rebound congestion and potential systemic effects. No specific malformation pattern has been reported. |
| Fetal Monitoring | For short-term topical use in pregnancy, routine monitoring is not required. If systemic absorption is suspected (e.g., maternal hypertension, tachycardia), monitor maternal blood pressure and heart rate. Fetal heart rate monitoring may be considered if maternal adverse effects occur or in cases of prolonged use. No specific fetal monitoring is mandated for standard use. |
| Fertility Effects | There are no known adverse effects of oxymetazoline on human fertility. Animal studies have not reported impaired fertility. The drug is not expected to affect reproductive organs or gametogenesis due to minimal systemic absorption. |